Bayesian optimal interval design
The Bayesian optimal interval design compares an observed toxicity proportion with prespecified boundaries to guide the next dose.
Why this level?
not one of the five research areas this hierarchy covers. NHMRC 2009 sourceDose selection is a feasibility and safety question, not one of the five research areas this hierarchy covers. It does not establish comparative treatment benefit.
Fit
When to use it, and when not to
Use it when
- You need to select a dose for later study under a prespecified safety plan.
- The toxicity outcome and its observation window can guide the next allocation.
Not when
- You need to choose the allocation approach first. Compare dose-finding designs. Read: Choosing a dose-finding design
- You need to establish treatment benefit against a comparator. Use a randomized trial. Read: Randomized controlled trial
Before you start
What you need
- Toxicity definition and targetDefine a dose-limiting toxicity and the full assessment window before recruitment.
- Dose levels and safety limitsFix the starting dose, allowed moves, stopping rules and independent safety oversight.
- Simulated trial scenariosVary toxicity curves, accrual and delayed harm. Check selection accuracy and exposure to unsafe doses.
- Pending toxicity is not absence of toxicity.How to check: Wait for the required window or use a validated extension designed for partial follow-up.
- The dose ordering and safety target fit the treatment.How to check: Toxicity-focused dose selection may not identify the best benefit-risk balance or biological dose.
Plain language
How it works
Choose a target toxicity probability and define acceptable departures before recruitment. Derive escalation and de-escalation boundaries from those choices. After completed outcomes, compare the observed toxicity proportion at the current dose with these boundaries. Escalate at or below the lower boundary. Stay strictly between boundaries, and de-escalate at or above the upper boundary. Apply the overdose elimination rule too. Use the prespecified final dose-selection procedure at the end.
BOIN means Bayesian optimal interval. Its next-dose rule and final dose choice are different steps. Simulate both, with stopping and safety restrictions. A design for completed outcomes should not treat pending toxicity as a negative result.
Worked example
A worked example
- Setting
- An early-phase trial follows a prespecified toxicity window.
- Question
- What do the observed counts imply under the stated design?
- Approach
- At one dose, two of eight patients have completed toxicity outcomes. Apply the protocol boundaries, not thresholds chosen from these results.
- Result
- Two of eight patients have toxicities: 25 in 100.
- What it means
- The observed share alone does not determine the action. The target, boundaries, safety rule and final selection rule must be specified.
In practice
Recent studies PubMed search · not vetted
Watch out
Common mistakes
The one to remember
BOIN boundaries are design choices fixed before recruitment. The current proportion does not replace overdose elimination or the final selection procedure.
- Equating dose selection with proof of efficacy.Instead: Selection is uncertain. Confirm benefit in a suitable later trial.
- Changing allocation rules after a worrying result.Instead: Apply the prespecified safety and stopping rules with the safety team.
Inside Mallard
How Mallard uses this
Plans do not link to this design yet. Mallard has no sample-size form for the Bayesian optimal interval design. A plan sized by simulation gets no headline sample size; Mallard does not run that simulation.
design.boin, the id a plan cue records.How to report it
Use CONSORT-DEFINE to report the dose-selection goal, toxicity window, allocation, safety and stopping rules, deviations and participant flow. Separate observed toxicity from model estimates. State the final dose recommendation and its uncertainty. A reporting guideline is not a design manual: use it to make the study transparent, not as a substitute for careful design. Check the target journal's own requirements as well, which this page cannot know.
Related Learn pages
Related designs and methods
Evidence
Sources & further reading
- Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials (opens in a new tab) · Clin Cancer Res · doi 10.1158/1078-0432.CCR-16-0592
- Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance (opens in a new tab) · BMJ · doi 10.1136/bmj-2023-076387